Lerapolturev infusion for recurrent glioblastoma
Part of Cancer clinical trials.
This trial tests a new drug called lerapolturev (also known as PVSRIPO) for people whose glioblastoma has come back. The drug is delivered directly into the tumor during a small procedure. Researchers want to see if it can help control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with recurrent glioblastoma (a type of brain tumor).
- You are able to care for yourself most of the day (KPS score 70% or higher).
- You have adequate blood cell counts and organ function (like liver and kidneys).
- You have had a polio vaccine booster within 1 to 6 weeks before starting the study drug.
- You can have an MRI with contrast and are willing to follow birth control rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (D2C7-IT and 2141-V11) given directly into the brain after surgery for people with recurrent glioblastoma. The goal is to see if this treatment is safe and can help control the tumor.
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This trial is testing a new drug (JL15003) given directly into the brain tumor using a small device called an Ommaya reservoir. It is for people whose glioblastoma has come back despite standard treatments. You will need to have had a polio vaccine booster before starting.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
Hear when a new Recurrent Supratentorial Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.